.png){kind=icon}
.png){kind=icon}
Return
Does OptiTROP-Lung05 open a new frontier for first-line ADC–ICI combinations in NSCLC?
.png){kind=icon}
PRE
AI
M
DOI：10.1038/s41571-026-01183-6.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Interim data from the phase III OptiTROP-Lung05 trial demonstrate that adding the TROP2-targeted antibody–drug conjugate sacituzumab tirumotecan to pembrolizumab improves progression-free survival in patients with PD-L1-positive advanced-stage non-small-cell lung cancer. Herein, I present several questions that need to be addressed before this combination can be considered a new standard of care, such as effect on overall survival, long-term safety, global generalizability and biomarker refinement.
Journal
IF:
82.2
Papers:
2.3K
Citations:
3.3W
Organization
Cited Papers